MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.061
https://www.valueinhealthjournal.com/article/S1098-3015(18)33361-8/fulltext
Title : MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33361-8&doi=10.1016/j.jval.2018.09.061
First page :
Section Title :
Open access? : No
Section Order : 7
Categories :
Tags :
Regions :
ViH Article Tags :